ATE330601T1 - Sulfonamide als matrix-metalloproteinase inhibitoren - Google Patents

Sulfonamide als matrix-metalloproteinase inhibitoren

Info

Publication number
ATE330601T1
ATE330601T1 AT01922101T AT01922101T ATE330601T1 AT E330601 T1 ATE330601 T1 AT E330601T1 AT 01922101 T AT01922101 T AT 01922101T AT 01922101 T AT01922101 T AT 01922101T AT E330601 T1 ATE330601 T1 AT E330601T1
Authority
AT
Austria
Prior art keywords
mmp
matrix metalloproteinase
sulfonamides
metalloproteinase inhibitors
present
Prior art date
Application number
AT01922101T
Other languages
English (en)
Inventor
Young-Jun Park
Hae-Young Bae
Ji-Uk Yoo
Myeong-Yun Chae
Sang-Hyun Paek
Hye-Kyung Min
Hyun-Gyu Park
Choon-Ho Ryu
Kyung-Chul Kim
Jeoung-Wook Lee
Original Assignee
Samsung Electronics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2000-0018328A external-priority patent/KR100384693B1/ko
Priority claimed from KR10-2000-0018327A external-priority patent/KR100372757B1/ko
Priority claimed from KR10-2000-0018431A external-priority patent/KR100405912B1/ko
Application filed by Samsung Electronics Co Ltd filed Critical Samsung Electronics Co Ltd
Application granted granted Critical
Publication of ATE330601T1 publication Critical patent/ATE330601T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Dental Preparations (AREA)
AT01922101T 2000-04-07 2001-04-07 Sulfonamide als matrix-metalloproteinase inhibitoren ATE330601T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2000-0018328A KR100384693B1 (ko) 2000-04-07 2000-04-07 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
KR10-2000-0018327A KR100372757B1 (ko) 2000-04-07 2000-04-07 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
KR10-2000-0018431A KR100405912B1 (ko) 2000-04-08 2000-04-08 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체

Publications (1)

Publication Number Publication Date
ATE330601T1 true ATE330601T1 (de) 2006-07-15

Family

ID=36686651

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922101T ATE330601T1 (de) 2000-04-07 2001-04-07 Sulfonamide als matrix-metalloproteinase inhibitoren

Country Status (9)

Country Link
US (1) US6548667B2 (de)
EP (1) EP1208092B1 (de)
JP (1) JP4008708B2 (de)
CN (1) CN1366524A (de)
AT (1) ATE330601T1 (de)
AU (1) AU4888401A (de)
CA (1) CA2372352A1 (de)
DE (1) DE60120881T2 (de)
WO (1) WO2001077092A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100405912B1 (ko) * 2000-04-08 2003-11-14 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
KR100384693B1 (ko) * 2000-04-07 2003-05-22 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) * 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
WO2003082272A1 (en) * 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US8088737B2 (en) 2003-04-04 2012-01-03 Incyte Corporation Compositions, methods and kits relating to Her-2 cleavage
BRPI0414916A (pt) * 2003-09-30 2006-11-07 Tibotec Pharm Ltd métodos para a preparação de compostos de sulfonamida de benzoxazol e intermediários dos mesmos
WO2005058808A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
RU2006125441A (ru) 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные циклопропана и их фармацевтическое применение
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
US7145040B2 (en) * 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
SE0403118D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 2
EP1883652A2 (de) * 2005-05-26 2008-02-06 Bristol-Myers Squibb Company N-terminal modifizierte glp-1-rezeptormodulatoren
EP1976873A2 (de) * 2006-01-11 2008-10-08 Brystol-Myers Squibb Company Modulatoren des humanen glukagon-ähnlichen peptids 1 und ihre anwendung in der behandlung von diabetes und verwandten leiden
US20100022457A1 (en) * 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US20080044326A1 (en) * 2006-07-04 2008-02-21 Esencia Co., Ltd. Sterilizer for baby products
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US9044454B2 (en) * 2010-03-10 2015-06-02 Northwestern University Regulation of microvasculature occlusion
CA2896053A1 (en) 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
CN107635959A (zh) * 2015-06-10 2018-01-26 住友化学株式会社 氨基甲酸酯化合物的制造方法
CN108929559B (zh) * 2018-07-03 2020-05-15 珠海黑马医学仪器有限公司 一种新型蓝光电泳核酸染料及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
ES2233275T3 (es) * 1995-12-08 2005-06-16 Agouron Pharmaceuticals, Inc. Intermediarios que sirven para la preparacion de inhibidores de metaloproteinasas.
JP2000515153A (ja) * 1996-07-22 2000-11-14 モンサント カンパニー チオールスルホンアミド メタロプロテアーゼインヒビター
GB9715962D0 (en) 1996-08-23 1997-10-01 Zeneca Ltd Sulfonamides
AU735013B2 (en) * 1996-09-04 2001-06-28 Warner-Lambert Company Matrix metalloproteinase inhibitors and their therapeutic uses
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
ES2176913T3 (es) * 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
WO1999041246A1 (en) 1998-02-11 1999-08-19 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
PA8469601A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Procedimiento para alquilar sulfonamidas impedidas estericamente

Also Published As

Publication number Publication date
EP1208092A1 (de) 2002-05-29
JP4008708B2 (ja) 2007-11-14
AU4888401A (en) 2001-10-23
US6548667B2 (en) 2003-04-15
DE60120881D1 (de) 2006-08-03
EP1208092B1 (de) 2006-06-21
EP1208092A4 (de) 2003-01-02
WO2001077092A1 (en) 2001-10-18
DE60120881T2 (de) 2007-01-18
US20020169314A1 (en) 2002-11-14
CN1366524A (zh) 2002-08-28
CA2372352A1 (en) 2001-10-18
JP2003530389A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
ATE330601T1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
IS7337A (is) Nikótínamíð afleiður nytsamlegar sem P38 hindrar
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
NO971537D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer for metalloproteaser
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
BR0210874A (pt) Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
NZ526913A (en) Inhibitors of cruzipain and other cysteine proteases
NO983991L (no) Serin-protease-inhibitorer
ES2171945T3 (es) Derivados aromaticos de amidina que sirven de inhibidores selectivos de la trombina.
NO20003828L (no) 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinase inhibitorer
ATE356114T1 (de) Inhibitoren von metalloproteinasen
BR9813719A (pt) Agentes terapêuticos
ATE253359T1 (de) Antithrombotische mittel
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
ATE373636T1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
NO20030675D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
ATE286395T1 (de) Antithrombotische mittel
BRPI0415885A (pt) ácidos piperidinil-e piperazinil-sulfonilmetilidroxámicos e sua utilização como inibidores de protease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties